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Abstract 
Subcutaneously infused apomorphine, used in the treatment of Parkinson’s Disease, is associated 
with the development of hard nodules at the infusion site. They may interfere with absorption of the 
drug and cause difficulty finding a suitable infusion site. Relatively little is known about aetiological 
factors for the development of the nodules, or about which treatments are found most effective. 
A case series assessment was used to investigate nodule formation, effects and management in 24 
individuals receiving apomorphine by infusion. Demographics and clinical information, opinions of 
patients and carers, and physical and sonographic assessment data were obtained.  
Difficulty finding infusion sites was the most commonly reported problem caused by nodules. Tissue 
changes varied considerably, and included nodule formation, dermal thickening and diffuse oedema. 
No single factor was found to substantially influence severity, but poor hygiene and needle-changing 
technique appeared to exacerbate the problem. Various treatments were employed, and 
therapeutic ultrasound was reported particularly beneficial.  Tissue evaluation by visual inspection, 
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Introduction 
Apomorphine hydrochloride is used in the treatment of people with later stage Parkinson’s Disease 
(PD), particularly those who are experiencing disabling “on-off” motor fluctuations (Tyne et al., 
2004). It is administered subcutaneously, usually to the lower abdomen or thigh, by injection or 
continuous infusion (Lees and Turner, 2002). A common side effect is the development of 
subcutaneous nodules around the site of entry (Pietz et al., 1998, Hagell and Odin, 2001, Deleu et al., 
2004). The nodules can be tender and they may become infected, necessitating antibiotic treatment 
or surgical debridement (Pietz et al., 1998). They may also create a barrier to absorption of the drug 
and so reduce its efficacy (Manson et al., 2001, Lees and Turner, 2002). Plasma apomorphine 
concentrations and Parkinsonian symptoms have been found to vary erratically when there is 
profuse nodule formation(Manson et al., 2001).  
A majority of people on infused apomorphine develop nodules (Deleu et al., 2004). A new nodule 
may form every time the infusion needle is re-sited, which normally happens on a daily basis. 
Nodules may resolve with time but in some cases tissue becomes hardened over extensive areas, 
reducing the sites available for placing infusion needles and thus making nodule formation even 
more problematic.  
Histological studies have concluded that apomorphine nodules are a form of panniculitis - a local 
inflammatory reaction in the subcutaneous tissue (Acland et al., 1998, van Laar et al., 1998). 
However there is little published work describing them, or concerning factors contributing to their 
development and resolution. Improved knowledge of causation and progression may provide a 
clearer rationale for the management of problematic cutaneous changes associated with the use of 
this drug.  
The purpose of the present study was to describe the range of cutaneous and subcutaneous changes 
associated with the use of infused apomorphine,  the factors that may impact on their development 
and resolution, and the perspectives of the people who are affected by them. The study took the 
form of a case series assessment. 
Participants and methods 
People receiving apomorphine for PD and experiencing nodule formation were recruited from the 
PD clinic of University College Hospital, London. All eligible patients were invited to participate. 
Information sheets were sent to all registering an interest, and informed written consent was 
obtained from those who were willing to take part. Of 27 people approached, 24 agreed to 
participate.  The study protocol was approved by the institutional ethics committee and its scientific 
review panel.  
Demographic and clinical information was gathered on participants from hospital notes, and 
assessments were carried out either during a routine outpatient check-up, on a home visit, or by 
telephone interview (2 people remote from the study site). Participants and their carers were 
interviewed to gain insights into their experience with nodules, the difficulties they caused, and 
management strategies adopted.  Physical assessment was carried out using visual inspection and 
palpation. This was followed by sonographic imaging using a Sonosite Micromaxx System 3.4.1  with 
a 13-6 MHz linear array transducer (Sonosite Ltd, Hitchin, UK).  Where possible, participants 
identified nodules as recently formed (within the previous few days) or longer-standing (several 
weeks or older). Nearby areas that were not used for infusion needle-siting were also assessed to 
obtain comparison data for unaffected tissue. The assessment was carried out jointly by a 
physiotherapist and a sonographer, and additional data was provided by the clinic’s PD specialist 
nurse. 
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Qualitative data from participant and carer interviews was analysed to identify common features 
and differences. Demographic and medical history data were compared with measurements 
obtained from sonography, to investigate whether there were any associations between them. 
Results 
Demographic and clinical data for the participants are provided in table 1. 
Table 1: Characteristics of study participants.  
 Parameter values 
  
Sample size 24 
Sex 12 M, 12 F 
Age / yr 65 (47-81) 
Time since PD diagnosis / yr 20 (9-32) 
Time on apomorphine / yr 6 (0.25-15) 
Infusion rate / mg/hr 5.9 (3.25-13.75) 
Infusion time / hr 14 (10-24) 
Infusion dose / mg/day 79.5 (43.0-160) 
Infusion site
a
 A=21 , T=8 , O=3 
Values are given as mean (range); 
a
 A=abdomen; T=thigh; O=other sites (lower back and posterior shoulder). In 
some cases participants used several sites for infusion. 
Nodule formation and associated problems 
Nodule formation had been observed by most participants immediately or a few weeks after 
infusion treatment commenced. A nodule typically formed within hours of the infusion needle being 
removed, although sometimes no reaction was evident. Nodules would sometimes resolve within a 
few days or weeks, but a proportion lasted longer, some for months, and others gradually coalescing 
with others to form permanent hardened areas. For the majority of people experiencing significant 
nodule formation, the difficulty in finding useable infusion sites was cited as the most significant 
problem. As more areas become unusable, infusions are focussed in smaller areas and so cutaneous 
reactions occur closer together, exacerbating the problem. For some participants this was a source 
of anxiety as they anticipated a time when they would be unable to find a site for infusion: some had 
been forced to inject into tender or hardened tissue because they saw no other option, with 
consequent pain and the possibility of poor absorption of apomorphine. Pain or tenderness were 
reported by most participants, but in only one case was this regarded as a barrier to finding infusion 
sites. Nodules were usually at their most tender in their early stages of development, and 
occasionally became numb with age. Cosmetic appearance was not reported as of concern to any 
participant. 
Prevention and management 
All participants said they changed the infusion sites daily, usually alternating between left and right 
sides. However some – usually those who self-injected – tended to use comparatively small areas of 
the abdomen repeatedly, which meant that needle trauma and apomorphine reactions were 
focused in those areas. Some were unsure about – or reluctant to try – using other sites such as 
thigh or shoulder for needle siting, even when nodule formation was limiting the available infusion 
areas. In some cases it appeared that healthcare professionals who carried out needle changes were 
not adhering to best practice, for instance by  
• siting needles too low in the abdomen or oriented vertically 
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• poor application of dressings so that needles were exposed or not held in place adequately 
• poor hygiene  
• insufficient site rotation 
Observation during  home visits indicated that self-administration was also not always satisfactory. 
Examples included poor hygiene, frequent casual re-siting of needles felt to be uncomfortable, 
removal of the needle by tugging the line sharply, and siting the needle in areas that were visibly 
inflamed. A shallow angle of needle insertion appeared to be a source of trauma, leading to greater 
irritation, staining of the skin and in one case was associated with necrosis and scarring of surface 
tissue.  
Most participants had tried various prophylactics or remedies for nodule formation or associated 
tenderness. These included use of a hand-held electric massager, application of silicone gel patches 
or topical preparations (Sudocrem, E45 or other emollients, Fucidin and Emla) after removal of the 
needle. There were mixed views on the effectiveness of these measures. Massage and silicone 
patches were considered beneficial for tissue softening by those who used them, but participant 
descriptions suggested that the topical preparations were used for pain relief rather than for 
resolving nodules. Four people had received courses of ultrasound therapy previously and reported 
it helpful for resolving nodules. One person who had received a single session of US therapy did not 
find it beneficial. 
Tissue assessment 
Visual inspection and palpation revealed considerable variation in surface markings and tissue 
hardness. In some cases there was little evidence of deterioration; in others, blanched areas over 
hardened tissue, discoloration consistent with bruising or necrosis, broken skin and evidence of local 
infection was observed. Figure 1 provides a photographic example of observed surface changes. 
 
Fig 1: severely affected abdomen showing surface bruising and scarring, erythema and necrosis. 
 
 
Sonography of affected tissue revealed substantial departures from normal tissue appearance in 
many cases, including dermal thickening, irregularity and loss of definition of dermal-subdermal 
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boundary, and diffuse oedematous changes in the subcutaneous layer. Strong shadowing seen in 
one case may have been due to calcification or fibrotic changes. Palpable nodules varied in size 
between a few millimetres and several centimetres across. In some cases they had indistinct, 
lobulated forms.  Figures 2 provides example of sonographic  images of normal and affected tissue. A 
three-point scale describing and quantifying the extent of tissue changes was developed as a result 
of these observations, presented in table 3. A fuller account and discussion of the sonographic 
features identified has been published (Edwards et al., 2008). 
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Table 3: Sonographic assessment of extent of tissue changes.  
Severity Sonographic features 
1  
mild 
• Discernible focal hypoechoic or hyperechoic areas in Field of View (FOV) 
• Normal dermal thickness (typically 2mm) 
• Slight variations in dermal-subdermal boundary 




• 1-2 focal hypoechoic or hyperechoic areas in FOV 
• Focal areas <1cm across 
• Slight thickening of dermis (typically 3-4mm) 
• Irregularity / some loss of definition in dermal-subdermal boundary 





• lobulated or >2 distinct focal hypoechoic or hyperechoic areas in FOV 
• Focal areas >1cm across 
• Significant thickening of dermis (>4mm) 
• Irregularity / substantial loss of definition in dermal-subdermal boundary 
• Substantial diffuse changes in subdermis (loss of normal lobulated appearance of 
adipose tissue. 
• Evidence of focal fibrosis or calcification 
Scores assigned on the basis of overall appearance, all features not necessarily present in each case. 
 
Fig 2: Sonographic images of abdominal tissue of a  61-year-old female, receiving apomorphine for 3 
years. (a) normal abdominal subcutaneous tissue; (b)  affected tissue. Depth 3cm, identical US 
settings for both images. 
 (a) (b) 
  
 
Severity scores using the sonographic scale were assigned to each participant and non-parametric 
tests were used to check for associations between these scores and a variety of potential risk 
factors.  SPSS 14 was used to calculate Kendall’s tau and Spearman’s rho, with significance set at 
p=0.05. No significant correlations were found between severity scores and time since diagnosis 
with PD, Hoehn and Yahr stage, age,  body mass index, daily or hourly dose of apomorphine, hours 
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spent each day on infusion or reported history of allergic response. A moderate negative correlation 
was found, however, between severity score and number of years on apomorphine.  
Table 4: Tests of correlation between sonography severity score and years on apomorphine 
Test Coefficient P 
Spearman’s  ρ -0.46 0.03 
Kendall’s  τ -0.39 0.03 
 
Several other trends were observed. Participants using the narrower gauge needle for infusion 
tended to have less severe tissue changes, and those siting their own needle (as opposed to having 
another person do it) tended to have more severe tissue changes. People with lean body frames 
often presented with smaller, well-defined nodules, whilst those with more adipose tissue at the 
infusion sites usually developed larger but more diffuse hardened areas. Both presentations could 
be problematic. Cases of poor needle-changing practice often coincided with significant 
deterioration in tissue appearance and quality, although not necessarily more profuse nodule 
formation.  
Discussion 
Nodule formation and associated tissue changes can present a considerable problem to people 
receiving infused apomorphine. Whilst nodules are thought to be reactions to the drug itself(Acland 
et al., 1998), other factors are likely to contribute to the severity of the tissue changes that have 
been described. Participant accounts and clinician observations suggest that infusion practices vary 
considerably, and departures from best practice may exacerbate reactions to the infusion.  
The relatively small sample size may account for the fact that no statistically significant correlations 
were detected between most potential risk factors and sonography severity scores. Apomorphine 
dose is likely to be a risk factor because people receiving continuous infusions, rather than (lower 
dose) intermittent injections, tend to experience the most significant cutaneous reactions (Hughes 
et al., 1993, Deleu et al., 2004). In the clinic from which participants were recruited for this study, 
only patients receiving apomorphine by infusion were reported to have significant nodule formation. 
However the variation in severity observed in people on similar doses suggests that dose is not the 
only factor involved. The negative association between severity score and years on apomorphine 
appears counter-intuitive. It may also be that the longer people are receiving apomorphine, the 
more adept they become at preventing or treating nodule formation. Also, the severity score applies 
to sonography of only one area and does not take account of how extensively they are distributed. 
Nevertheless these findings support the contention that the severity of nodules depends on a variety 
of factors, not just apomorphine regime. Evaluating the contributions of potential risk factors, and 
interaction effects, would require a larger sample.  
In the meantime, there may be scope for lessening nodule formation and other tissue reactions by 
attending to factors such as  
• needle type 
• needle-siting technique 
• use of a wider area and rotation  - not just alternation from side to side, 
• improved hygiene  
• prompt treatment of affected tissue.  
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Although guidelines for the use of apomorphine and management of nodules are available (Swinn et 
al., 2005, Todd and James, 2008), greater attention to the education of those receiving the drug, and 
of carers (family or health professionals) involved in infusion management, may be required. 
Varying reports of the efficacy of different treatments suggest that sub-group analysis may help 
identify people more likely to respond to a particular treatment.  The sonography severity scale 
developed in this study may be a useful measure for researchers to gauge the extent of tissue 
changes and the effectiveness of any treatments applied, but it remains to be validated. Caution is 
required in the use of sonographic  images because their correspondence to tissue changes has not 
been verified by correlation with histology.  Such studies are difficult as they may require large 
incisional biopsies (Requena, 2007). For the purposes of clinical assessment, palpation and 
observation may be more practical ways of monitoring nodule severity and deciding when further 
intervention is indicated.  
For those experiencing nodules and other tissue reactions, hardening of the tissue was the biggest 
problem, primarily because it limits sites available for infusion.  Clearly, where prophylaxis has not 
been successful,  an effective treatment for these side effects is highly desirable.  In addition to 
comments from participants in this study, our group has substantial anecdotal evidence from 
clinicians who have used therapeutic ultrasound, suggesting that it can be an effective treatment for 
apomorphine nodules. A pilot trial of the treatment by our group, reported elsewhere(Poltawski et 
al., In Press), was encouraging. Guidelines for ultrasound treatment based on our experience are 
available at http://www.electrotherapy.org/modalities/apomorphine.html.  The possibility of 
portable therapeutic ultrasound units that can be used by patients at home is being investigated, 
since this would enable them to manage treatment independently. A combination of clean and 
careful needle-changing technique, deep tissue massage and therapeutic ultrasound may offer the 
best prevention and management plan for nodules. 
The small sample size used in this study, and their recruitment from a single clinic, suggests that its 
findings may not be generalisable to the wider population. However, the demographic and clinical 
characteristics of the sample are similar to those reported in other studies (Hagell and Odin, 2001, 
Deleu et al., 2004, Katzenschlager et al., 2005). 
 
Conclusion 
This study has identified problems that are associated with the use of subcutaneous infusions of 
apomorphine hydrochloride.  The severity of reaction appears to be affected by a numerous of 
factors, and better education of patients are carers regarding nodule prevention and management is 
recommended.   Sonographic data are suggestive of broader structural changes in the tissue than 
has been previously reported. Palpation and sonography may be useful instruments for evaluation of 
tissue, and for monitoring effectiveness of treatment.  Further studies to investigate factors 




Subcutaneous nodules are a common and potentially problematic side-effect of apomorphine 
infusion for Parkinson’s Disease 
Nodule severity may be affected by infusion-siting and needle-changing practices as much as by use 
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of the drug itself 
Education of those responsible for administration of apomorphine infusions may be beneficial in 
reducing nodule formation 
A range of treatments are available for nodules, and therapeutic ultrasound should be considered as 
part of a management strategy 
Sonography may be a useful outcome measure in studies of nodule treatment effectiveness  
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